Tepkinly
Safety Classified by Officially
Tepkinly Active substance Epcoritamab Holder AbbVie Belgium SA/NV Status Running Indication Epcoritamab in combination with lenalidomide and rituximab (R²) for the treatment of relapsed or refractory Follicular Lymphoma (FL), previously treated with at least 1 line of systemic chemoimmunotherapy (2L+). …
This is an extract. The publication continues at the source.
Read the original at the source: https://www.famhp.be/fr/usage_humain/medicaments/medicaments/recherche_developpement/usage_compassionnel_programmes_133
Officially imported this from Federal Agency for Medicines and Health Products (FAMHP)’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- Federal Agency for Medicines and Health Products (FAMHP) — imported from official source
- Official source
- https://www.famhp.be/en/rss.xml RSS
- Imported
- October 03, 2026 20:37
- Versions
- 1 recorded
- Identity
-
110400 at https://www.famhp.be